Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

TL-118-anti-angiogenic treatment in pancreatic cancer: a case report.

Breuer S, Maimon O, Appelbaum L, Peretz T, Hubert A.

Med Oncol. 2013;30(2):585. doi: 10.1007/s12032-013-0585-9. Epub 2013 Apr 23.

PMID:
23609193
2.

TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.

Komar-Stossel C, Gross E, Dery E, Corchia N, Meir K, Fried I, Abramovitch R.

PLoS One. 2014 Mar 6;9(3):e90224. doi: 10.1371/journal.pone.0090224. eCollection 2014.

3.

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW.

Oncologist. 2001;6(6):488-95.

4.

Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.

Joka M, Boeck S, Zech CJ, Seufferlein T, Wichert Gv, Licht T, Krause A, Jauch KW, Heinemann V, Bruns CJ.

Anticancer Drugs. 2014 Oct;25(9):1095-101. doi: 10.1097/CAD.0000000000000146.

PMID:
25029236
5.
6.

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.

Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, Wong H, Brekken RA.

BMC Cancer. 2008 Nov 27;8:352. doi: 10.1186/1471-2407-8-352.

7.

Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.

Petrioli R, Roviello G, Fiaschi AI, Laera L, Marrelli D, Roviello F, Francini E.

Cancer Chemother Pharmacol. 2015 Apr;75(4):683-90. doi: 10.1007/s00280-015-2683-1. Epub 2015 Jan 25.

PMID:
25618415
9.

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).

Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, Raoul JL, Bachellier P, Dufour P, Moehler M, Weber A, Lang H, Rogiers X, Clavien PA.

BMC Cancer. 2011 Aug 10;11:346. doi: 10.1186/1471-2407-11-346.

10.

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.

Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek GV.

Ann Oncol. 2003 Jan;14(1):97-104.

PMID:
12488300
11.

Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.

Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R.

Clin Cancer Res. 2000 May;6(5):1936-48.

12.

Gemcitabine: progress in the treatment of pancreatic cancer.

Heinemann V.

Oncology. 2001;60(1):8-18. Review.

PMID:
11150902
13.

[A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine as second-line chemotherapy].

Kawamoto K, Yamaguchi K, Okabe M, Tsuruta A, Morimoto Y, Niwano M, Sano K, Paku T, Imai S, Yoshida Y, Ito T, Ogasahara K.

Gan To Kagaku Ryoho. 2007 Jul;34(7):1131-4. Japanese.

PMID:
17637556
14.

The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.

Yapp DT, Wong MQ, Kyle AH, Valdez SM, Tso J, Yung A, Kozlowski P, Owen DA, Buczkowski AK, Chung SW, Scudamore CH, Minchinton AI, Ng SS.

Angiogenesis. 2016 Apr;19(2):229-44. doi: 10.1007/s10456-016-9503-z. Epub 2016 Mar 9.

15.

S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.

Kim MK, Lee KH, Jang BI, Kim TN, Eun JR, Bae SH, Ryoo HM, Lee SA, Hyun MS.

Jpn J Clin Oncol. 2009 Jan;39(1):49-53. doi: 10.1093/jjco/hyn126. Epub 2008 Dec 5.

PMID:
19060295
16.

Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.

Lee J, Park JO, Kim WS, Lee SI, Song SY, Lim DH, Choi SH, Heo JS, Lee KT, Lee JK, Kim K, Jung CW, Im YH, Lee MH, Kang WK, Park K.

Oncology. 2004;66(1):32-7.

PMID:
15031596
17.

Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.

Li Y, Sun J, Jiang Z, Zhang L, Liu G.

J Chemother. 2015 Aug;27(4):227-34. doi: 10.1179/1973947815Y.0000000013. Epub 2015 Mar 20.

PMID:
25790948
18.

Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer.

Müerköster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Fölsch UR, Schäfer H.

Int J Cancer. 2003 Apr 20;104(4):469-76.

19.

Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.

Damaraju VL, Bouffard DY, Wong CK, Clarke ML, Mackey JR, Leblond L, Cass CE, Grey M, Gourdeau H.

BMC Cancer. 2007 Jul 3;7:121.

20.

Supplemental Content

Support Center